Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes. Population based cohort study. General practices contributing data to the UK Clinica...
Gespeichert in:
| Veröffentlicht in: | BMJ 2018-12, Vol.363, p.k4880-k4880 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | k4880 |
|---|---|
| container_issue | |
| container_start_page | k4880 |
| container_title | BMJ |
| container_volume | 363 |
| creator | Abrahami, Devin Douros, Antonios Yin, Hui Yu, Oriana Hy Faillie, Jean-Luc Montastruc, François Platt, Robert W Bouganim, Nathaniel Azoulay, Laurent |
| description | To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.
Population based cohort study.
General practices contributing data to the UK Clinical Practice Research Datalink.
154 162 adults newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2017, followed until 31 March 2018.
Use of DPP-4 inhibitors and GLP-1 receptor agonists was modelled as a time varying variable and compared with use of other second or third line antidiabetic drugs. All exposures were lagged by one year to account for cancer latency and to minimise reverse causality. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance analysis was conducted using the World Health Organization's global individual case safety report database, VigiBase, to estimate reporting odds ratios of cholangiocarcinoma.
During 614 274 person years of follow-up, 105 incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years). Use of DPP-4 inhibitors was associated with a 77% increased hazard of cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use of GLP-1 receptor agonists was associated with an increased hazard with a wide confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both associated with increased reporting odds ratios for cholangiocarcinoma, compared with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95 to 7.58, respectively).
Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes. |
| doi_str_mv | 10.1136/bmj.k4880 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6278586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2161063890</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-a10c9edfe954345b59371d0f7bf079ecbdc523418805851a7a3eceb32c18a5653</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS0EoqvSA18AWeIChxRPHCc2B6SqAlppJS5wthzb2Xib2MF2Fu23x6V_gJ5G8vz8ZuY9hF4DOQeg7Yd-3p_fNJyTZ2gDHWsr4JQ-RxsimKg4UH6CzlLaE0Jq2nHRspfohBIGvAW-QYdrr6PNzuNeJWuwiesuYeUNji7d4DBgPYZJ-Z0LWkXtfJgVVnPwO7yo7KzPCf9yecT5uFhcY-NUb7NNH_ESlnUqSHiQ1mEMMeOUV3N8hV4Makr27L6eoh9fPn-_vKq2375eX15sK93QLlcKiBbWDFawhjasZ4J2YMjQ9QPphNW90aymDZTrGWegOkWttj2tNXDFWkZP0ac73WXtZ2t02TeqSS7RzSoeZVBO_t_xbpS7cJBt3XHG2yLw_k5gfPLt6mIrb9-Kq0TUdXOAwr67HxbDz9WmLGeXtJ2KfTasSdbQAmkpF6Sgb5-g-7BGX6woFCO1AErh73AdQ0rRDo8bAJG34csSvvwTfmHf_HvpI_kQNf0NNT2rhA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2150291331</pqid></control><display><type>article</type><title>Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><creator>Abrahami, Devin ; Douros, Antonios ; Yin, Hui ; Yu, Oriana Hy ; Faillie, Jean-Luc ; Montastruc, François ; Platt, Robert W ; Bouganim, Nathaniel ; Azoulay, Laurent</creator><creatorcontrib>Abrahami, Devin ; Douros, Antonios ; Yin, Hui ; Yu, Oriana Hy ; Faillie, Jean-Luc ; Montastruc, François ; Platt, Robert W ; Bouganim, Nathaniel ; Azoulay, Laurent</creatorcontrib><description>To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.
Population based cohort study.
General practices contributing data to the UK Clinical Practice Research Datalink.
154 162 adults newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2017, followed until 31 March 2018.
Use of DPP-4 inhibitors and GLP-1 receptor agonists was modelled as a time varying variable and compared with use of other second or third line antidiabetic drugs. All exposures were lagged by one year to account for cancer latency and to minimise reverse causality. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance analysis was conducted using the World Health Organization's global individual case safety report database, VigiBase, to estimate reporting odds ratios of cholangiocarcinoma.
During 614 274 person years of follow-up, 105 incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years). Use of DPP-4 inhibitors was associated with a 77% increased hazard of cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use of GLP-1 receptor agonists was associated with an increased hazard with a wide confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both associated with increased reporting odds ratios for cholangiocarcinoma, compared with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95 to 7.58, respectively).
Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.</description><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1756-1833</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.k4880</identifier><identifier>PMID: 30518618</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Aged ; Bile Duct Neoplasms - chemically induced ; Cancer ; Cholangiocarcinoma ; Cholangiocarcinoma - chemically induced ; Cohort analysis ; Cohort Studies ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-peptidase IV ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Endocrinology and metabolism ; Family medical history ; Female ; Gallbladder diseases ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide-1 Receptor - agonists ; Health risk assessment ; Human health and pathology ; Humans ; Hypoglycemic Agents - adverse effects ; Incretins - adverse effects ; Insulin ; Latency ; Life Sciences ; Male ; Middle Aged ; Odds Ratio ; Peptidase ; Pharmaceutical sciences ; Pharmacology ; Pharmacovigilance ; Population studies ; Population-based studies ; Prescription drugs ; Primary care ; Proportional Hazards Models ; Risk Factors ; Santé publique et épidémiologie ; Side effects ; Sulfonylurea Compounds - adverse effects ; Thiazolidinediones ; Thiazolidinediones - adverse effects ; Weight control</subject><ispartof>BMJ, 2018-12, Vol.363, p.k4880-k4880</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2018BMJThis is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0/.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to 2018 BMJ</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-a10c9edfe954345b59371d0f7bf079ecbdc523418805851a7a3eceb32c18a5653</citedby><cites>FETCH-LOGICAL-c437t-a10c9edfe954345b59371d0f7bf079ecbdc523418805851a7a3eceb32c18a5653</cites><orcidid>0000-0001-5162-3556 ; 0000-0003-0100-4073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30518618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-02309224$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Abrahami, Devin</creatorcontrib><creatorcontrib>Douros, Antonios</creatorcontrib><creatorcontrib>Yin, Hui</creatorcontrib><creatorcontrib>Yu, Oriana Hy</creatorcontrib><creatorcontrib>Faillie, Jean-Luc</creatorcontrib><creatorcontrib>Montastruc, François</creatorcontrib><creatorcontrib>Platt, Robert W</creatorcontrib><creatorcontrib>Bouganim, Nathaniel</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><title>Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study</title><title>BMJ</title><addtitle>BMJ</addtitle><description>To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.
Population based cohort study.
General practices contributing data to the UK Clinical Practice Research Datalink.
154 162 adults newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2017, followed until 31 March 2018.
Use of DPP-4 inhibitors and GLP-1 receptor agonists was modelled as a time varying variable and compared with use of other second or third line antidiabetic drugs. All exposures were lagged by one year to account for cancer latency and to minimise reverse causality. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance analysis was conducted using the World Health Organization's global individual case safety report database, VigiBase, to estimate reporting odds ratios of cholangiocarcinoma.
During 614 274 person years of follow-up, 105 incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years). Use of DPP-4 inhibitors was associated with a 77% increased hazard of cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use of GLP-1 receptor agonists was associated with an increased hazard with a wide confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both associated with increased reporting odds ratios for cholangiocarcinoma, compared with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95 to 7.58, respectively).
Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.</description><subject>Aged</subject><subject>Bile Duct Neoplasms - chemically induced</subject><subject>Cancer</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - chemically induced</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-peptidase IV</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>Endocrinology and metabolism</subject><subject>Family medical history</subject><subject>Female</subject><subject>Gallbladder diseases</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Health risk assessment</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Incretins - adverse effects</subject><subject>Insulin</subject><subject>Latency</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Peptidase</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology</subject><subject>Pharmacovigilance</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Prescription drugs</subject><subject>Primary care</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>Santé publique et épidémiologie</subject><subject>Side effects</subject><subject>Sulfonylurea Compounds - adverse effects</subject><subject>Thiazolidinediones</subject><subject>Thiazolidinediones - adverse effects</subject><subject>Weight control</subject><issn>0959-8138</issn><issn>1756-1833</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU9v1DAQxS0EoqvSA18AWeIChxRPHCc2B6SqAlppJS5wthzb2Xib2MF2Fu23x6V_gJ5G8vz8ZuY9hF4DOQeg7Yd-3p_fNJyTZ2gDHWsr4JQ-RxsimKg4UH6CzlLaE0Jq2nHRspfohBIGvAW-QYdrr6PNzuNeJWuwiesuYeUNji7d4DBgPYZJ-Z0LWkXtfJgVVnPwO7yo7KzPCf9yecT5uFhcY-NUb7NNH_ESlnUqSHiQ1mEMMeOUV3N8hV4Makr27L6eoh9fPn-_vKq2375eX15sK93QLlcKiBbWDFawhjasZ4J2YMjQ9QPphNW90aymDZTrGWegOkWttj2tNXDFWkZP0ac73WXtZ2t02TeqSS7RzSoeZVBO_t_xbpS7cJBt3XHG2yLw_k5gfPLt6mIrb9-Kq0TUdXOAwr67HxbDz9WmLGeXtJ2KfTasSdbQAmkpF6Sgb5-g-7BGX6woFCO1AErh73AdQ0rRDo8bAJG34csSvvwTfmHf_HvpI_kQNf0NNT2rhA</recordid><startdate>20181205</startdate><enddate>20181205</enddate><creator>Abrahami, Devin</creator><creator>Douros, Antonios</creator><creator>Yin, Hui</creator><creator>Yu, Oriana Hy</creator><creator>Faillie, Jean-Luc</creator><creator>Montastruc, François</creator><creator>Platt, Robert W</creator><creator>Bouganim, Nathaniel</creator><creator>Azoulay, Laurent</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5162-3556</orcidid><orcidid>https://orcid.org/0000-0003-0100-4073</orcidid></search><sort><creationdate>20181205</creationdate><title>Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study</title><author>Abrahami, Devin ; Douros, Antonios ; Yin, Hui ; Yu, Oriana Hy ; Faillie, Jean-Luc ; Montastruc, François ; Platt, Robert W ; Bouganim, Nathaniel ; Azoulay, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-a10c9edfe954345b59371d0f7bf079ecbdc523418805851a7a3eceb32c18a5653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Bile Duct Neoplasms - chemically induced</topic><topic>Cancer</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - chemically induced</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-peptidase IV</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>Endocrinology and metabolism</topic><topic>Family medical history</topic><topic>Female</topic><topic>Gallbladder diseases</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Health risk assessment</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Incretins - adverse effects</topic><topic>Insulin</topic><topic>Latency</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Peptidase</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology</topic><topic>Pharmacovigilance</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Prescription drugs</topic><topic>Primary care</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>Santé publique et épidémiologie</topic><topic>Side effects</topic><topic>Sulfonylurea Compounds - adverse effects</topic><topic>Thiazolidinediones</topic><topic>Thiazolidinediones - adverse effects</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abrahami, Devin</creatorcontrib><creatorcontrib>Douros, Antonios</creatorcontrib><creatorcontrib>Yin, Hui</creatorcontrib><creatorcontrib>Yu, Oriana Hy</creatorcontrib><creatorcontrib>Faillie, Jean-Luc</creatorcontrib><creatorcontrib>Montastruc, François</creatorcontrib><creatorcontrib>Platt, Robert W</creatorcontrib><creatorcontrib>Bouganim, Nathaniel</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abrahami, Devin</au><au>Douros, Antonios</au><au>Yin, Hui</au><au>Yu, Oriana Hy</au><au>Faillie, Jean-Luc</au><au>Montastruc, François</au><au>Platt, Robert W</au><au>Bouganim, Nathaniel</au><au>Azoulay, Laurent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>2018-12-05</date><risdate>2018</risdate><volume>363</volume><spage>k4880</spage><epage>k4880</epage><pages>k4880-k4880</pages><issn>0959-8138</issn><eissn>1756-1833</eissn><eissn>1468-5833</eissn><abstract>To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.
Population based cohort study.
General practices contributing data to the UK Clinical Practice Research Datalink.
154 162 adults newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2017, followed until 31 March 2018.
Use of DPP-4 inhibitors and GLP-1 receptor agonists was modelled as a time varying variable and compared with use of other second or third line antidiabetic drugs. All exposures were lagged by one year to account for cancer latency and to minimise reverse causality. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance analysis was conducted using the World Health Organization's global individual case safety report database, VigiBase, to estimate reporting odds ratios of cholangiocarcinoma.
During 614 274 person years of follow-up, 105 incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years). Use of DPP-4 inhibitors was associated with a 77% increased hazard of cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use of GLP-1 receptor agonists was associated with an increased hazard with a wide confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both associated with increased reporting odds ratios for cholangiocarcinoma, compared with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95 to 7.58, respectively).
Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>30518618</pmid><doi>10.1136/bmj.k4880</doi><orcidid>https://orcid.org/0000-0001-5162-3556</orcidid><orcidid>https://orcid.org/0000-0003-0100-4073</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8138 |
| ispartof | BMJ, 2018-12, Vol.363, p.k4880-k4880 |
| issn | 0959-8138 1756-1833 1468-5833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6278586 |
| source | Jstor Complete Legacy; MEDLINE |
| subjects | Aged Bile Duct Neoplasms - chemically induced Cancer Cholangiocarcinoma Cholangiocarcinoma - chemically induced Cohort analysis Cohort Studies Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-peptidase IV Dipeptidyl-Peptidase IV Inhibitors - adverse effects Endocrinology and metabolism Family medical history Female Gallbladder diseases Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Health risk assessment Human health and pathology Humans Hypoglycemic Agents - adverse effects Incretins - adverse effects Insulin Latency Life Sciences Male Middle Aged Odds Ratio Peptidase Pharmaceutical sciences Pharmacology Pharmacovigilance Population studies Population-based studies Prescription drugs Primary care Proportional Hazards Models Risk Factors Santé publique et épidémiologie Side effects Sulfonylurea Compounds - adverse effects Thiazolidinediones Thiazolidinediones - adverse effects Weight control |
| title | Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A09%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incretin%20based%20drugs%20and%20risk%20of%20cholangiocarcinoma%20among%20patients%20with%20type%202%20diabetes:%20population%20based%20cohort%20study&rft.jtitle=BMJ&rft.au=Abrahami,%20Devin&rft.date=2018-12-05&rft.volume=363&rft.spage=k4880&rft.epage=k4880&rft.pages=k4880-k4880&rft.issn=0959-8138&rft.eissn=1756-1833&rft_id=info:doi/10.1136/bmj.k4880&rft_dat=%3Cproquest_pubme%3E2161063890%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2150291331&rft_id=info:pmid/30518618&rfr_iscdi=true |